Phosphoproteomics is the large-scale study of protein phosphorylation, a critical post-translational modification (PTM) that regulates virtually every cellular process. In the context of neurodegenerative diseases, phosphoproteomics provides a powerful approach to understand the dysregulated signaling pathways that contribute to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Protein phosphorylation involves the reversible addition of phosphate groups to specific amino acid residues—primarily serine, threonine, and tyrosine. This modification acts as a molecular switch, altering protein conformation, activity, localization, and protein-protein interactions. In neurodegenerative diseases, aberrant phosphorylation leads to: [1]
Phosphoproteomics enables systematic mapping of these alterations, providing mechanistic insights and identifying therapeutic targets. [2]
The low abundance of phosphorylated peptides (often <1% of total peptides) necessitates enrichment prior to mass spectrometry analysis. [3]
IMAC uses transition metal ions (Fe3+, Ga3+, Ti4+) coordinated to chelating groups to capture phosphorylated peptides. IMAC offers: [4]
TiO2 selectively binds phosphate groups through Lewis acid-base interactions. TiO2 is favored for: [5]
Anti-phosphotyrosine antibodies enable selective enrichment of tyrosine-phosphorylated peptides, critical for studying receptor tyrosine kinase signaling in neurodegeneration. [6]
Cell Signaling Technology's PTMScan methodology uses anti-phosphotyrosine or anti-phospho-motif antibodies for affinity purification, enabling targeted phosphoproteomics. [7]
LFQ compares precursor ion intensities across samples without metabolic labeling, suitable for clinical specimens.
SILAC incorporates labeled arginine and lysine, enabling precise quantification in cell culture models.
These isobaric labeling strategies allow multiplexed quantification (up to 16 samples with TMTpro), ideal for time-course and cohort studies.
Off-line high-pH reversed-phase fractionation combined with enrichment improves coverage of the phosphoproteome.
Mass spectra must localize phosphorylation to specific residues. Algorithms include:
Bioinformatic tools predict upstream kinases:
| Database | Description | URL |
|---|---|---|
| PhosphoSitePlus | Curated PTM data | phosphosite.org |
| Phospho.ELM | Kinase substrates | phospho.elm.eu.org |
| dbPTM | PTM database | dbptm.biocuckoo.org |
| PhosPhAt | Plant phosphoproteomics | phosphat.mpimp-golm.mpg.de |
Key kinases implicated in neurodegenerative diseases:
| Kinase | Disease | Role |
|---|---|---|
| GSK-3 beta | AD, PD | Tau phosphorylation, neuroinflammation |
| CDK5 | AD, PD, ALS | Tau phosphorylation, neuronal death |
| LRRK2 | PD | Synaptic function, autophagy |
| JNK | AD, PD, HD | Stress response, apoptosis |
| ERK1/2 | AD, PD | Synaptic plasticity, survival |
| CK2 | AD | Tau phosphorylation |
Reduced phosphatase activity contributes to hyperphosphorylation:
Phosphoproteomic studies in AD have identified [1]:
Phosphoproteomics in PD reveals [2]:
ALS phosphoproteomics has uncovered:
| Method | Coverage | PTM Focus | Advantages | Limitations |
|---|---|---|---|---|
| Phosphoproteomics | ~10,000-50,000 sites | Phosphorylation | Direct pathway mapping | Enrichment bias |
| Total Proteomics | ~10,000-15,000 proteins | All proteins | Global abundance | No PTM resolution |
| Ubiquitinomics | ~5,000-10,000 sites | Ubiquitination | Degradation pathway insights | Similar enrichment challenges |
| Acetylomics | ~3,000-8,000 sites | Acetylation | Metabolic regulation | Limited coverage |
| Glycoproteomics | ~5,000-10,000 sites | Glycosylation | Secreted/ membrane proteins | Heterogeneity |
| Spatial Proteomics | ~2,000-8,000 proteins | Subcellular localization | Compartment-specific | Lower depth |
Combining phosphoproteomics with other modalities provides comprehensive insights:
Phosphoproteomics identifies druggable targets:
Zhong S, et al. Phosphoproteomic analysis of patient-derived neurons reveals Parkinson's disease mechanisms. Nature Communications. 2022. ↩︎
Mair W, et al. Temporal phosphoproteome profiling across Alzheimer's disease progression. Neurobiology of Aging. 2019. ↩︎
Humphrey SJ, et al. PTMScan: Technology for proteomic analysis of phosphorylation. Cold Spring Harbor Protocols. 2015. ↩︎
Liu Y, et al. LRRK2 kinase activity regulates phosphorylated substrates in Parkinson's disease. Neurobiology of Disease. 2021. ↩︎
Hornbeck PV, et al. PhosphoSitePlus: A comprehensive resource for investigating protein post-translational modifications. Genome Research. 2012. ↩︎
Mann M, et al. Phosphoproteomics in translational research: A neuromedicine perspective. Science Translational Medicine. 2022. ↩︎
Oliveira J, et al. Amyloid-beta and tau pathology in Alzheimer's disease: Phosphoproteomic insights. Nature Reviews Neurology. 2023. ↩︎